Catalyst Enterprises

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases. The company's flagship product, Firdapse (amifampridine), is the first and only approved treatment in the U.S. for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst has expanded its portfolio through strategic acquisitions, including the rights to Fycompa (perampanel) for epilepsy and Agamree (vamorolone) for Duchenne muscular dystrophy. The company continues to evaluate additional rare disease opportunities to broaden its commercial footprint and address significant unmet medical needs.